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A B S T R A C T
Background
Candidate human papillomavirus (HPV) vaccines have demonstrated almost 90%-100%
efficacy in preventing persistent, type-specific HPV infection over 18 mo in clinical trials. If these
vaccines go on to demonstrate prevention of precancerous lesions in phase III clinical trials,
they will be licensed for public use in the near future. How these vaccines will be used in
countries with national cervical cancer screening programmes is an important question.
Methods and Findings
We developed a transmission model of HPV 16 infection and progression to cervical cancer
and calibrated it to Finnish HPV 16 seroprevalence over time. The model was used to estimate
the transmission probability of the virus, to look at the effect of changes in patterns of sexual
behaviour and smoking on age-specific trends in cancer incidence, and to explore the impact
of HPV 16 vaccination. We estimated a high per-partnership transmission probability of HPV 16,
of 0.6. The modelling analyses showed that changes in sexual behaviour and smoking
accounted, in part, for the increase seen in cervical cancer incidence in 35- to 39-y-old women
from 1990 to 1999. At both low (10% in opportunistic immunisation) and high (90% in a
national immunisation programme) coverage of the adolescent population, vaccinating
women and men had little benefit over vaccinating women alone. We estimate that vaccinating
90% of young women before sexual debut has the potential to decrease HPV type-specific (e.g.,
type 16) cervical cancer incidence by 91%. If older women are more likely to have persistent
infections and progress to cancer, then vaccination with a duration of protection of less than 15 y
could result in an older susceptible cohort and no decrease in cancer incidence. While
vaccination has the potential to significantly reduce type-specific cancer incidence, its
combination with screening further improves cancer prevention.
Conclusions
HPV vaccination has the potential to significantly decrease HPV type-specific cervical cancer
incidence. High vaccine coverage of women alone, sustained over many decades, with a long
duration of vaccine-conferred protection, would have the greatest impact on type-specific
cancer incidence. This level of coverage could be achieved through national coordinated
programmes, with surveillance to detect cancers caused by nonvaccine oncogenic HPV types.
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Introduction
Human papillomavirus (HPV) is a common sexually trans-
mitted infection and has been shown in epidemiological and
molecular studies to be a necessary aetiologic agent for
cervical cancer [1–3]. At least 30 HPV types infect the genital
area, of which 15 are classiﬁed as high risk, that is, having
oncogenic potential [1]. Human papillomavirus type 16 is the
most common high-risk type, accounting for more than half
(56%) of all cervical cancers [4]. Persistent infection with
high-risk types is the most important risk factor for cervical
cancer [5]. This long premalignant course of HPV infection
means that screening programmes can detect and treat early
disease and prevent progression to cervical cancer.
In Finland, rates of invasive cervical cancer (ICC) incidence
in women have changed signiﬁcantly over the last four
decades, with overall rates decreasing from 14.1 cases per
100,000 women in 1960 to 3.8 per 100,000 in 2000 [6]. While
other factors, such as a decrease in fertility, may be important
in explaining the decrease seen in cervical cancer incidence
[7], comprehensive screening programmes have contributed
to the decrease in cancer cases in the Nordic countries and
the UK [8–10].
Despite this overall decline, unfortunately there has been a
recent trebling of the rate among Finnish women aged 30–39
y [11], from 2.85 ICC cases per 100,000 women in 1990 to 9.3
cases per 100,000 in 1999, and a doubling of the rate for
women aged 25–49 y [6]. Looking at trends in HPV infection,
a steady increase in HPV 16 antibody incidence of 7% per
year from 1983 to 1997, and increased seroprevalence of HPV
16 from 17% to 24%, were found among the Finnish
maternity cohort between the ages of 23 and 31 y [12]. For
an individual, serology to detect past infection with HPV is an
imperfect test: 55%–92% of women with HPV DNA
detectable at the cervix seroconvert over 6–12 mo, depending
on the HPV type and persistence of the infection [13–16].
However, at the population level, longitudinal changes in
HPV 16 antibody levels were detected among Finnish women.
In considering the factors responsible for the changes seen
in HPV and cervical cancer epidemiology, viral factors
(increased virulence and predominance of high-risk types),
host factors (changes in behaviour and immunity), and
changes in screening and diagnosis were considered. There
have been no changes in organised screening or diagnostics as
such. Surveys in 1971, 1992, and 1999 showed changes in
reported sexual behaviour among women in Finland; between
1971 and 1999 the average lifetime number of sexual partners
for women increased from 2.6 to 7.7, and the average age of
sexual debut for women decreased from 18.9 to 16.6 y (Table
1) [17]. In addition to HPV infection, smoking is a consistent
cofactor for carcinoma of the cervix across retrospective and
prospective studies [18]. Studies that have looked at the risk
for cervical cancer among HPV-positive women who have
ever smoked have reported odds ratios between 2 and 5
compared to HPV positive never smokers. Smoking started to
become more common amongst Finnish women in the 1960s,
and it has been estimated that in the late 60s and early 70s
approximately 5%–10% of Finnish women smoked [19]. In
1978 the National Public Health Institute in Finland started
an annual national adult health behaviour monitoring system
which included questions on smoking. They found that
between 1979 and 1991 the percentage of Finnish women
who smoked increased from 17% to 21% and then decreased
to 19% in 1994 [19].
Mathematical models provide a framework within which we
can explore patterns of risk behaviour, HPV infection, and
progression to cervical cancer [20–22]. Here we explore the
observed epidemiology of HPV 16 infection and cervical
cancer in Finland and predict the potential impact of
candidate HPV vaccines.
The candidate HPV virus-like particle vaccines are promis-
ing. A randomized, double-blind, phase II trial of an HPV 16
vaccine found that, over a median of 17 mo, the vaccine had
an estimated efﬁcacy of 100% (95% conﬁdence interval [CI],
90%–100%) and 91% (95% CI, 80%–97%) in preventing
persistent and any HPV 16 infection, respectively [23]. A
randomised, double-blind phase II trial of a bivalent HPV 16/
18 vaccine was estimated according to protocol analysis as
having an efﬁcacy of 100% (95% CI, 47%–100%) and 92%
(95% CI, 65%–98%) over 18 mo against persistent and all
HPV 16/18 infections, respectively [24]. A randomised,
double-blind, placebo-controlled phase II trial of a quad-
rivalent vaccine targeting high-risk HPV types 16 and 18 and
low-risk HPV types 6 and 11 (which cause benign genital
warts) found that combined incidence of persistent infection
or disease with HPV 6, 11, 16, or 18 fell by 90% (95% CI,
71%–97%) in those assigned vaccine compared with those
assigned placebo over 36 mo [25]. In a phase III multinational
study evaluating the same quadrivalent HPV 6, 11, 16, and 18
vaccine, immunisation prevented 100% (95% CI, 76%–100%)
of HPV 16/18-related cervical intraepithelial neoplasia 2/3,
adenocarcinoma in situ, and squamous cell carcinoma
according to the protocol analysis at 24 mo [26].
A prophylactic vaccine may eventually reduce the inci-
dence of cervical cancer, but in countries with well-
established and effective cervical cancer screening pro-
Table 1. Finnish Patterns of Sexual Behaviour over Time
Year Mean Lifetime Number of Sexual Partners (95% CI) Mean Age at Sexual Debut (95% CI)a
Women Men Women Men
1971 2.6 (2.4–2.8) 11.0 (9.2–12.8) 18.9 (18.7–19.1) 17.8 (17.5–18.1)
1992 6.8 (5.9–7.7) 12.4 (10.7–14.1) 17.1 (16.9–17.3) 17.4 (17.1–17.7)
1999 7.7 (6.5–8.9) 12.4 (9.7–15.1) 16.6 (16.4–16.8) 17.7 (17.3–18.1)
Source of data was Haavio-Mannila et al. [17].
aMean age at sexual debut for women was derived from reported ages for all women, so it reflects an average across preceding periods. The same method is applied for men.
DOI: 10.1371/journal.pmed.0030138.t001
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grammes, questions about how the vaccine will be used need
to be addressed. In this paper we quantify the effects of
vaccinating men and women compared to vaccinating women
only, vaccination before and after sexual debut, immunisa-
tion through national programmes versus opportunistic
vaccination, duration of vaccine-conferred protection, and
vaccination combined with screening programmes.
Methods
Model Definition and Parameter Values
A compartmental deterministic model of HPV 16 infection
and progression to cervical cancer was developed building on
a previous model through the addition of type-speciﬁc
immunity [27]. Figure 1 provides a schematic representation
of the model for women and men. In women, the model
describes the ﬂow of incident cases from the acquisition of
asymptomatic HPV infection through premalignant disease
to ICC, although most HPV infections regress spontaneously.
Considering a single virus type (HPV 16), we assume that
regression results in lifelong acquired immunity. However,
HPV 16 serum antibody test sensitivity and speciﬁcity [28]
and gradual loss of a detectable antibody response are
included to allow the comparison of model results with
serological data, where false negatives will increase as a
function of time since infection [29,30]. The model allows for
screening and treatment and accounts for hysterectomy for
nonmalignant disease. The model equations, which are solved
numerically in a Cþþ program, are presented in Dataset S1
and Protocol S1 with details of the parameter values used.
The model population was stratiﬁed according to age (0 y
to 84 y) in 5-y cohorts (0–4, 5–9. . .80–84) and sexual activity
class (1, 2. . .4), deﬁned according to the rate of sexual partner
change [31]. With sexual behaviour available only from cross-
sectional studies at two time points, each of which included
multiple birth cohorts, an understanding of the changes in
sexual behaviour as a function of age and time is difﬁcult,
especially in the light of potential social desirability biases
[32] (Table 1 presents a summary, and a full description can
be found in Table S1). We derived an annual number of new
partners from the reported number of lifetime partners
stratiﬁed by age and divided by the estimated duration of
activity based on the difference between the age at survey and
the average age at sexual debut estimated during that survey
[17]. Men and women report different average numbers of
sexual partners, with this difference most marked in earlier
surveys; such differences are common in sexual behaviour
surveys, and a range of biases have been investigated [33].
Initially, because men and women report different annual
numbers of new partners, behaviours were estimated from
the mean of behaviours reported by men and women. For
both sexes, the observed age of sexual debut and number of
sexual partners changed between the surveys, which are
reﬂected in the model with a one-off change in rates of sexual
partner acquisition and age at sexual debut. The inﬂuence of
the timing of this step change was explored. The model was
run to equilibrium using the sexual behaviour data from the
1971 survey, with changes in rates of partner change and age
at sexual debut from the 1992 survey introduced later. The
size, sex, and age distribution and rates of birth and death of
the population were based on the demography of Finland (see
Table S2) [34].
A simple screening and treatment scenario was considered
that is based on the reported age-speciﬁc percentage of
eligible women screened through the national Finnish
screening programme (see Table S3). The screened age
groups were 30–60 y, using cytologic Pap smear screening,
and the screening interval was 5 y [35]. Screening and
treatment, which prevents progression from high-grade
squamous intraepithelial lesions (HSIL) to ICC is more
effective if repeated in individuals, as initial false negatives
are likely to be detected [36]. To allow for this effect of
repeated screening in a model that does not track individuals,
we adjusted screening efﬁcacy upwards as a function of age.
The benign hysterectomy rate was estimated to be 20% for
women age 45–64 y, based on data from the Finnish National
Research and Development Centre for Welfare and Health
[37].
HPV progression and regression rates converted to
transition probabilities [38] were based on a review of studies
by Myers and colleagues [39] and Syrja¨nen and colleagues
[40]. The proportion of women assumed to be current
smokers was estimated from the annual national adult health
behaviour monitoring system conducted by the National
Public Health Institute in Finland from 1978 [19].
Figure 1. Model Schematic of HPV 16 Natural History in Women and
Men
(A) Susceptible women acquire HPV as determined by the force of
infection (k), which is the per susceptible risk of acquiring infection.
Asymptomatic HPV infection can progress to LSILs, HSILs, and ICC,
although most infections regress spontaneously to an immune state. Ten
percent of asymptomatic HPV progresses rapidly to HSIL. Screening and
treatment can prevent progression from HSIL to ICC. The model allows
for benign hysterectomy at any stage and accounts for loss of detectable
antibody over time.
(B) Susceptible men acquire HPV as determined by the force of infection
(k), which is the per-susceptible-individual risk of acquiring infection
from an infected woman. Infected men recover to an immune state.
DOI: 10.1371/journal.pmed.0030138.g001
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Estimating the Transmission Probability
An important epidemiological parameter is the risk of
transmission when an infectious individual is in contact with a
susceptible sexual partner. To estimate the value of this
transmission probability (deﬁned here per partnership), we
varied its value between its possible limits of 0 and 1 and
compared predicted age-speciﬁc seroprevalence of HPV 16
with those observed over time [12]. Because seroprevalence
was observed in women with at least two children, to allow for
comparability with the modelled seroprevalence a weighted
model prevalence was derived by age, according to the
distribution of reported numbers of children in the sexual
behaviour data used to deﬁne the model activity classes. In
addition, the predicted prevalence by age from the model was
adjusted for HPV 16 antibody test performance character-
istics, assuming a gradual loss of antibodies over time since
infection [29,30] along with speciﬁcity of 95% and sensitivity
of 55% [41–43]. The observed persistence of antibodies for no
more than 10 y after infection was generated by an annual 20%
rate of loss. In comparing the predicted and observed
prevalences, the maximum log likelihood was calculated for
different values of the transmission probability (b) [44]. The
maximum log likelihood equation can be found in Protocol S1.
The reported sexual partner numbers from the sexual
behaviour surveys may be underestimates if those with
extreme behaviours are not included in the small sample
due to social desirability biases [45]. Therefore, in addition to
the directly derived estimates of sexual partner change rates,
we also explored two sets of increased values. In one we
simply doubled the estimated rates compared to those
derived from observed data and, in the second, an extreme
set, we equated yearly rates of partner change with reported
lifetime numbers of partners.
Changing Patterns of Risk Behaviour and Disease
The estimate of seroprevalence as a function of age and
time included the effects of observed changes in risk
behaviour. Additionally, the changing pattern of incidence
of ICC was compared with model predictions. To compare
the modelled ICC associated with HPV 16 to the overall rates
reported to the Finnish Cancer Registry, we assumed that
HPV 16 accounted for 56% of ICC incidence in the data [4], a
value comparable to the population-attributable fraction of
61% for HPV 16 infection in squamous cell carcinoma
estimated by Laukkanen and colleagues in Finland (P.
Laukkanen and M. Lehtinen, unpublished data). The impact
of changes in number of partners, age of sexual debut, and
patterns of smoking on ICC incidence was explored with a
range of timing of changes. The proportion of women
smoking tobacco estimated in three-year periods was
included (Table S4), with an assumed doubling in progression
from high-grade dysplasia to ICC among those who were
current smokers at that particular time point in the model
[18,46]. Since the literature-derived progression rate of 0.013
per year was assumed to include smokers and nonsmokers, a
rate for smokers of 0.0214 and non-smokers of 0.0107 per
year was estimated if 20% of women smoked in the
population used for the overall estimate.
Modelling the Potential Impact of HPV 16 Vaccines
The model based on 1992 behaviours (with a doubling of
rates of partner change) and current screening programme
(every 5 y between 30 and 60 y of age [11]) was used to explore
the potential impact of vaccination with varying vaccine
coverage, age at vaccination, and duration of vaccine-
conferred protection. Model predictions for HPV 16 incident
premalignant lesions, seroprevalence, and age-speciﬁc cer-
vical cancer incidence are shown in Figures S1–S3. For the
vaccination base case we assumed that 90% of successive
cohorts of women alone were routinely vaccinated at the age
of 15 y (before sexual debut), and that the vaccine had 100%
efﬁcacy with a lifelong duration of protection.
Results
Using reported behaviours to estimate the partner change
rate, we found that the maximum likelihood value of the
transmission probability is its theoretical maximum of 1,
which generates a lower prevalence than that observed.
Statistically, this estimate is imposed by the constraint and
suggests that the estimated prevalence was too high, the rates
of sexual partner change was too low, or acquired immunity
might not give lifelong protection. Assuming that survey data
will underestimate sensitive sexual behaviour, a maximum
likelihood transmission probability (b) of 0.6 per sexual
partnership was derived, assuming a doubling of sexual
partner change rates, and 0.4 if annual partner change rates
are equated with lifetime reported partners. The likelihood
proﬁles for these estimates are shown in Figure S4. A small
95% conﬁdence interval was found (0.59–0.61), using the
change in log likelihood compared to the v2 distribution on
one degree of freedom when calculating the 95% conﬁdence
interval for b. However, this conﬁdence interval is not
reliable, because only one parameter in the model was varied,
and its estimate relies on other parameters in the model
being accurate. Clearly, the uncertainty in estimates of sexual
behaviour along with other potential errors in estimating
assumed parameter values and model structure result in great
uncertainty in our estimate of the transmission probability
per partnership. For example, an assumed overestimate of
HPV serology sensitivity would lead to an underestimate of
the transmission probability, and vice-versa for underesti-
mated sensitivity.
The modelled and observed incidence of cervical cancer
amongst 35- to 39-y-olds is compared in Figure 2, where the
change in sexual behaviour is insufﬁcient to account for all
the change in disease incidence. The model initially over-
estimates, and then underestimates, incidence of HPV 16
cervical cancer in women aged 35–39; in the model it
increases from 2.8/100,000 to 4.1/100,000 between 1985 and
1999, whereas the estimate from reported cases increased
from 2.0/100,000 to 4.8/100,000. Despite the change in
behaviour being detected in the 1992 survey, the change
could have occurred earlier, and the change in ICC incidence
is more consistent with a change in sexual behaviour in the
model in 1985 as shown in Figure 2. (The effect of
introducing the change in behaviour in 1992 in the model
is shown in Figure S5.) Further, Laukkanen and colleagues
found that HPV 16 seroprevalence started to increase from
1985 [12]. Introducing the effect of smoking into the model
improved the estimate for cancer incidence before 1979
(predicting 2.4 cases per 100,000 women) but, because the
proportion of women who smoke remained fairly stable
(around 20%) between 1978 and 1995, little change in cancer
PLoS Medicine | www.plosmedicine.org May 2006 | Volume 3 | Issue 5 | e1380627
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incidence is predicted around the time of the observed
change.
To explore the impact of vaccination, we assume an HPV
16 transmission probability per sexual partnership of 0.6,
with sexual behaviour based on reports in 1992 and double
the reported new sexual partners per year, and sexual debut
at 16.6 y for women and at 17.7 y for men. The vaccine was
assumed 100% efﬁcacious with a lifelong duration. Figure 3A
illustrates the impact of varying vaccine coverage on cervical
cancer incidence for vaccinating women alone or women and
men: at both low (10%) and high (90%) coverage, vaccinating
women and men has a small beneﬁt over vaccinating women
only (4% and 7%, respectively). Additionally, we illustrate a
‘‘reasonable’’ expected coverage using private, opportunistic
uptake of vaccine with 10% of 15-y-olds and a further 30% of
20-y-old women vaccinated. Whilst this coverage reduces
incidence of cervical cancer, its impact is secondary to that
achieved through widespread vaccination (e.g., 90% coverage
of women).
The equilibrium reduction in HPV 16-associated cancer
incidence is derived for a range of ages of vaccination with
90% coverage (Figure 3B). Assuming no decay in protection,
it is predictable that changing the age of vaccination before
the age of sexual debut has no impact on the equilibrium,
despite an earlier age at vaccination delaying declines in
disease incidence. Once the age of sexual debut has been
exceeded, the impact of vaccination declines as the age of
vaccination increases, because of prior infection.
The duration of vaccine-conferred protection has an
important impact on ICC incidence that depends on what
is assumed about the relationship between age and the
likelihood of an infection becoming persistent (Figure 3C). If
we assume that older women are more likely to have
persistent HPV infections and progress to cervical cancer,
then an average duration of vaccine-conferred protection of
10 y allows women to return to a susceptible state on loss of
vaccine protection at a later age, when they are more likely to
acquire persistent HPV infection and progress to ICC; an
increased incidence overall compared to no vaccination. This
increase could be prevented by adequate booster vaccination,
but also through screening, and is not observed when we
assume no age dependency in the likelihood of persistent
infections.
Figure 3D explores the effect of adding vaccination to
screening programmes. With neither intervention, the
predicted HPV 16 cervical cancer incidence is 7 cases per
100,000 women. With current screening protocols and no
vaccination, the modelled HPV 16 ICC incidence is 2.8 cases
per 100,000 women. Vaccinating 90% of women, without
screening, reduces modelled HPV 16 ICC incidence to 0.6
cases per 100,000 women, whereas vaccination and screening
every 10 y (rather than the current Finnish protocol of every
5 y), is predicted to result in 0.4 cases per 100,000 women.
Combining vaccination with the current Finnish screening
programme is predicted to reduce cancer incidence to 0.2
cases per 100,000 women.
Discussion
Hughes and colleagues have previously estimated the per-
partnership transmission probability of HPV to be 0.8 [21].
Our estimate of a similarly high transmission probability of
HPV 16 per sexual partnership is based on the observed
prevalence of antibody responses to this virus. The trans-
mission probability contributes to the potential for spread of
the infection and is one of the key variables in determining
the basic reproductive number of the virus. A high trans-
mission probability and consequent high basic viral repro-
ductive number requires a high efﬁcacy and high vaccine
coverage to eliminate the infection [47]. How reliable is our
high estimate of the transmission probability? While it is
possible to construct narrow conﬁdence intervals for our
estimate, this can be done only by ﬁxing the many other
parameter values. However, we can be comfortable that the
Figure 2. Observed versus Predicted Cervical Cancer Incidence
The observed HPV 16 ICC [6] incidence is compared to model predictions. Including the reported changes in sexual behaviour and smoking trends
among Finnish women allows the model prediction for HPV 16 ICC incidence to capture an increase in cancer incidence after 1991, but it doesn’t
capture the full magnitude of the change. The changes in sexual behaviour, which were reported in 1992, were implemented in the model in 1985,
because they could have occurred before 1992.
DOI: 10.1371/journal.pmed.0030138.g002
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value lies above 0.4, because this estimated transmission
probability emerges when we use the extreme values of
lifetime reported partners as yearly new partners. If we have
underestimated sensitivity or overestimated the loss of a
speciﬁc antibody response, then the prevalence used in
comparison to model estimates will be high, which would
lower the estimated transmission probability.
Further, caution is required because our assumption of
lifelong acquired protection is important. If protection is
lost, infected individuals would move back into the suscep-
tible class, and the epidemiology of HPV 16 would be very
different, with a high observed prevalence and seropreva-
lence possible with a much lower basic reproductive number
and transmission probability. This would greatly reduce the
vaccine efﬁcacy and coverage required for elimination with a
vaccine that did generate immune protection. It is also
important to note that our estimate is per sexual partnership,
not per sex act. The transmission probability per partnership
is obviously a function of the transmission probability per act
and the number of sex acts, but to estimate the transmission
probability per act requires either more detailed sexual
behaviour or epidemiological data. While we did not
explicitly explore the effect of condom use on our estimation
for the transmission probability, a meta-analysis of 20 studies
suggested that, while condoms may not prevent HPV
infection, they may protect against genital warts, cervical
Figure 3. The Impact of Varying the Target Population for HPV 16
Vaccination
(A) The effect of routinely vaccinating successive cohorts of men and
women compared to vaccinating women alone at low (10%) and high
(90%) coverage is shown. Vaccination of the given proportion of
adolescents is assumed to occur before sexual debut at age 15 y and
there is no screening. At 10% and 90% vaccine coverage vaccinating
women and men has a small benefit (4% and 7%, respectively) over
vaccinating women alone. Vaccinating 90% of women alone reduced ICC
incidence by 91%. Voluntary vaccination among 10% of 15-y-olds and
30% of susceptible 20-y-old women would reduce HPV 16 ICC incidence
by 43%.
(B) The impact of vaccination at different ages on HPV 16 ICC incidence
for vaccination of 90% of women alone is shown. Sexual debut for
women is at 16.6 y and 17.7 y for men. Vaccination at birth and at age 15
y generated the greatest reduction in ICC incidence, to 0.6 cases per
100,000 women, with a lag seen for vaccination at birth. Vaccination at
age 20 y produced a 63% decrease and at age 25 y, a 41% decrease, in
cancer incidence.
(C) The impact of varying duration of vaccine efficacy on the incidence of
ICC for vaccination of 90% of women alone before sexual debut is
illustrated. Because older women are assumed to be more likely to have
persistent infections (a precursor to cancer) than younger women, a
vaccine with duration of 15 y or less shifts incident infections to older
women (who are more likely to progress to cancer) and there is no
reduction in the incidence of ICC. Screening can ameliorate the small
increase in cancer incidence seen. If women at all ages are likely to have
transient infections, then ICC decreases with increasing vaccine duration
and vaccine duration of 15 y reduces ICC incidence by 70%. The
progression and regression rates according to age are described in
Dataset S1 and Protocol S1. Screening parameters are shown in Table S3.
(D) The incremental effect of adding vaccination to screening
programmes at different screening intervals is shown. Ninety percent
of women alone are routinely vaccinated before sexual debut at the age
of 15 y, and it is assumed that vaccine efficacy is 100% with lifelong
conferred protection against HPV type 16. Screening alone reduces HPV
16 cancer incidence from 7.0 to 2.8 cases per 100,000 women and
vaccination added to this strategy can reduce ICC incidence further to
0.2 cases per 100,000 women. Vaccination alone reduces ICC incidence
to 0.6 cases per 100,000 women. Changing the screening strategy
(doubling time between screening rounds to 10 y) at the same time as
vaccine introduction brings ICC incidence to 0.4 cases per 100,000
women.
DOI: 10.1371/journal.pmed.0030138.g003
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intraepithelial neoplasia 2 or 3 and ICC [48]. Also, using data
from the Finnish maternity cohort and the distribution of
reported numbers of children per woman in the sexual
behaviour component takes this limitation of condom use
into account.
We explored whether the observed increase in cervical
cancer incidence among Finnish women aged 35–39 y, from
3.7 cases per 100,000 women in 1985 to 7.7 per 100,000 in
1999 [6], could be explained by changes in sexual behaviour
or increases in smoking. While some of the change could be
explained through observed changes in sexual behaviour,
these were not entirely sufﬁcient. This suggests that other
cofactors also contributed to the observed increase. For
example, the decrease in age at sexual debut could expose
those with immature cervical transformation zones (the
region of the cervix where columnar epithelium replaces
squamous epithelium with an existing predilection to HPV
infection) to HPV infection [49], increasing susceptibility
further and enhancing the effect of changes in sexual risk
behaviour. Thus, decreased age at sexual debut could increase
disease in young women in two ways: (1) through increasing
time since infection and (2) through increased vulnerability
of the immature transformation zone. The two would be
difﬁcult to differentiate epidemiologically, and we included
only the former mechanism in our model. In the model,
changes in rates of sexual partner change rather than the age
at sexual debut had a greater effect on ICC incidence
(unpublished data). This increased risk associated with sexual
partners reﬂects risk of HPV infection rather than ICC risk
once infected.
Also, it is notable in this context that a new HPV type (HPV
45) is present in 19% of the Finnish ICC cases appearing in
fertile-aged women, i.e., especially those women who have
experienced the increase of ICC incidence since early 19909s
(M. Lehtinen, unpublished data). It is possible that an increase
in HPV 45 cancers accounted for some of the increase seen in
the overall incidence for cervical cancer among women aged
35–39 y.
Including trends in tobacco smoking and an associated
increase in progression to ICC improved the model pre-
diction prior to 1979. However, since the percentage of
women smoking between 1978 and 1995 was consistently
approximately 20%, smoking trends do not explain changing
incidence between 1985 and 1999. A more careful explora-
tion of age-speciﬁc patterns of tobacco smoking, to look at
cohort effects, may be warranted.
Oral contraceptive use and parity are aetiological cofactors
that may also account for some of the cervical cancer
incidence increase [18], whereas organised screening pro-
grammes for cervical cancer in Finland have been unchanged
since 1990, and changes in registration or diagnostic practices
are not thought important [11]. Changes in other cofactors,
such as diet and other sexually transmitted infections, might
also play a role in the increasing incidence of cervical cancer
in Finland.
Screening was incorporated into the model by representing
the same mass-screening coverage and efﬁcacy rates reported
in 1999 over time starting in 1950, because screening
coverage has not changed in the last 40 y. In 1999 the Finnish
national screening programme invited 80% of 30-y-old
women to screening, screened 60% of those invited—that
is, only 49% of those eligible [6]. Low participation in
organised screening was found to correlate well with high or
increased incidence of cervical carcinoma, so improved
screening participation would reduce the incidence of cancer
[11]. Among older women, aged 40–55 y, on average 72% of
eligible women are screened. With the 75% increase seen in
ICC among 35- to 39-y-olds, improved coverage to detect
precancerous lesions in 30-y-old women is necessary. For
simplicity, changing sexual behaviour practices and regular
and/or sporadic screening done in the private sector were not
modelled.
The impact of vaccination in our model is comparable with
ﬁndings from previous modelling exercises [21,22,50–52],
where high coverage of women alone, vaccination before
sexual debut, and long-term protection (or boosters) provid-
ing three to four decades of protection are required to
substantially reduce ICC incidence. A vaccine providing
protection of less than 15 y may generate unexpected
outcomes by shifting susceptibility in women to an older
age group, where they could have increased risk of
persistence. However, if age-speciﬁc patterns of persistence
are derived from following cohorts of infected women,
because older women infected at entry are more likely to
have a persistent infection, it seems possible that an observed
increase in persistent infection with increased age is an
artefact. It is possible that type replacement with nonvaccine
oncogenic HPV types could have a comparable effect, with a
perverse increase in cervical cancer incidence. This could be
avoided by including new oncogenic HPV types in the
booster vaccines.
In developed countries with low cervical cancer incidence,
vaccine coverage, in terms of both the target population and
oncogenic HPV types, needs to be high in order to sustain the
low ICC incidence associated with effective screening.
Continued screening programmes have the potential to
detect precancerous lesions in those not vaccinated and
lesions associated with nonvaccine HPV types. The most
effective strategy is vaccination combined with current
screening protocols, compared to both screening alone and
vaccination alone. However, cytological screening is costly,
and in choosing a cervical cancer prevention strategy, health
economic assessments of available options are warranted.
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Dataset S1. Model Equations
Found at DOI: 10.1371/journal.pmed.0030138.sd001 (189 KB DOC).
Figure S1. Model-Predicted Age-Speciﬁc Low- and High-Grade
Intraepithelial Lesion Incidence per 100,000 Women
The peak incidence for low-grade squamous intraepithelial lesions
(LSIL) in the model occurs at age 25 y for women, and for HSILs at
age 40. It is challenging to compare this model output to observed
data because screening, as implemented in the model using a simple
strategy of preventing progression from HSIL to cervical cancer, does
not change the predicted incidence of premalignant lesions.
However, the cytological Pap smear diagnostic test, with varying
sensitivity and speciﬁcity [36] and low to moderate interobserver
agreement [53,54], does change the observed incidence of dysplastic
lesions observed in follow-up treatment.
Found at DOI: 10.1371/journal.pmed.0030138.sg001 (92 KB DOC).
Figure S2. Observed HPV 16 Seroprevalence Compared to Model-
Predicted Seroprevalence for 26- to 31-y-Old Women between 1983
and 1997
The model underestimates HPV 16 seroprevalence, but captures the
trend over time.
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Found at DOI: 10.1371/journal.pmed.0030138.sg002 (88 KB DOC).
Figure S3. Observed HPV 16 Age-Speciﬁc Invasive Cervical Cancer
Incidence versus Model Prediction without Screening and with
Screening and Change in Behaviour
HPV 16 ICC incidence is shown for the model prediction before the
introduction of screening and with national screening and changes in
sexual behaviour and smoking compared to the observed cancer
incidence for Finland, 1999–2003 [6].
Found at DOI: 10.1371/journal.pmed.0030138.sg003 (88 KB DOC).
Figure S4. Likelihood Proﬁle for HPV Transmission Probability
Maximum log likelihood estimation for different patterns of sexual
behaviour (Table S1) is shown. Doubling the reported average
number of new sexual partners per year, to account for under-
reporting, shows 0.6 to be the best estimate of HPV 16 transmission
probability.
Found at DOI: 10.1371/journal.pmed.0030138.sg004 (88 KB DOC).
Figure S5. Effect of Changes in Sexual Behaviour
The observed incidence is compared to the model prediction. In this
case, the model changes in sexual behaviour occurred when they were
reported (1992), with the increase in model incidence lagging behind
the observed increase in incidence. Changes in patterns of behaviour
probably occurred before they were detected in the 1992 survey. (The
observed ICC incidence representing the proportion of cancers, 0.56,
as reported by the Finnish Cancer Registry for HPV 16.)
Found at DOI: 10.1371/journal.pmed.0030138.sg005 (89 KB DOC).
Protocol S1. Finnish Model Equations
Found at DOI: 10.1371/journal.pmed.0030138.sd002 (145 KB DOC).
Table S1. Distribution of the Sexually Active Population, by Age
Group, into Sexual Activity Groups for Finland
Found at DOI: 10.1371/journal.pmed.0030138.st001 (104 KB DOC).
Table S2. Demographic Rates for Finland
The demographic rates were taken from the Statistics Finland Web
site [34].
Found at DOI: 10.1371/journal.pmed.0030138.st002 (93 KB DOC).
Table S3. Effect of Cervical Cancer Screening Programmes in Finland
Found at DOI: 10.1371/journal.pmed.0030138.st003 (84 KB DOC).
Table S4. Percentage of Tobacco Smokers among Finnish Women
Aged 15–64 y
Statistics are from National Public Health Institute, Finland [19].
Found at DOI: 10.1371/journal.pmed.0030138.st004 (79 KB DOC).
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Patient Summary
Background. Human papillomavirus (HPV) is the name of a group of
viruses that includes more than 100 different strains or types; more than
30 of these viruses are sexually transmitted. Persistent infection with
high-risk types of HPV is the most important risk factor for cervical
cancer; the development of cervical cancer always is preceded by
infection with one of these viruses, although the opposite is not always
true; infection can occur without it leading to cancer. Nonetheless, as the
infection is necessary for cancer to develop, vaccination that prevents
HPV infection could potentially also prevent cervical cancer. Several such
vaccines have already been developed and tested.
Why Was This Study Done? HPV 16 is the most common high-risk type,
accounting for more than half (56%) of all cervical cancers. Trials with
vaccines against this virus suggest that they would be very effective—
almost 100%—at preventing infection. The authors wanted to look at
how vaccination might fit into current programmes against cervical
cancer.
What Did the Researchers Do and Find? The authors looked at survey
findings in Finland of how common HPV 16 infection was over a ten-year
period, and developed a mathematical way of looking at the possible
effect of HPV 16 vaccination on the development of cervical cancer. They
showed that changes in sexual behaviour and smoking accounted, in
part, for the increase seen in cervical cancer incidence in 35- to 39-year-
old women from 1990 to 1999. They estimated that vaccinating women
and men had little benefit over vaccinating women alone, and that
vaccinating 90% of young women before they became sexually active
could decrease HPV type-specific (e.g., type 16) cervical cancer incidence
by 91%.
What Do These Findings Mean? Models such as this one will be
important for those planning vaccination campaigns with vaccines
against HPV. Although the results are specific to the Finnish population
they are derived from, the method of modeling has more general
applicability and could be used to estimate the effect of vaccination and
other factors on the incidence of HPV-associated cervical cancer in other
settings.
Where Can I Get More Information Online? Medline Plus has a page of
links to HPV information:
http://www.nlm.nih.gov/medlineplus/hpv.html
Medline Plus also has links to information on cervical cancer:
http://www.nlm.nih.gov/medlineplus/cervicalcancer.html
The CDC also has information on HPV:
http://www.cdc.gov/std/HPV
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